STOCK TITAN

Mangoceuticals (MGRX) completes $272,000 private placement of common shares

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Mangoceuticals, Inc. entered into a Subscription Agreement with an accredited investor, selling 850,000 shares of restricted common stock at $0.32 per share for total proceeds of $272,000. The investor receives piggyback registration rights for one year, meaning the shares can be included in certain future registration statements. The shares were issued in a private placement relying on exemptions under Section 4(a)(2) and Rule 506 of Regulation D, with no underwriters, no commissions paid, and standard transfer restrictions and legends applied.

Positive

  • None.

Negative

  • None.
Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 3.02 Unregistered Sales of Equity Securities Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Shares issued 850,000 shares Restricted common stock sold in private placement
Share price $0.32 per share Subscription Agreement with accredited investor
Gross proceeds $272,000 Total consideration for 850,000 shares
Registration rights period 1 year Piggyback registration rights following subscription dates
Subscription Agreement financial
"entered into a Subscription Agreement with an accredited investor"
A subscription agreement is a legal contract in which an investor agrees to buy a specific number of a company’s shares or other securities under set terms, including price, payment method and conditions for closing the sale. It matters to investors because it legally locks in their purchase and the company’s obligations, determines ownership percentage and any investor rights, and can include conditions or promises that affect future control or returns—like signing a detailed purchase order for equity.
accredited investor regulatory
"entered into a Subscription Agreement with an accredited investor"
An accredited investor is an individual or entity that meets certain financial criteria, such as having a high income or significant net worth, allowing them to invest in private or less regulated investment opportunities. This status matters because it grants access to investments that are often riskier or less available to the general public, reflecting a higher level of financial knowledge or resources.
piggyback registration rights regulatory
"includes piggyback registration rights for a period of one year"
A contractual right that lets existing shareholders join a company’s planned public sale of stock so they can sell their own shares at the same time under the same paperwork. It matters to investors because it gives insiders and early holders an easier, often faster way to convert shares to cash, while also potentially increasing the number of shares offered and affecting the share price — like catching a scheduled bus instead of hiring a private ride to get where you need to go.
Section 4(a)(2) regulatory
"pursuant to Section 4(a)(2) and/or Rule 506 of Regulation D"
Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.
Rule 506 of Regulation D regulatory
"pursuant to Section 4(a)(2) and/or Rule 506 of Regulation D"
Rule 506 of Regulation D is a U.S. Securities and Exchange Commission exemption that lets companies sell securities privately without registering them with the SEC, similar to a private party invitation rather than a public auction. It matters to investors because it determines how much information they’ll receive, who can buy (accredited vs. non-accredited), whether public advertising is allowed, and how easily the investment can be resold — all factors that affect risk, transparency and liquidity.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
false 0001938046 0001938046 2026-06-29 2026-06-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): June 29, 2026

 

MANGOCEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Texas   001-41615   87-3841292

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

17130 N. Dallas Parkway, Suite 240

Dallas, Texas

  75248
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (214) 242-9619

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 Par Value Per Share   MGRX  

The Nasdaq Stock Market LLC

(Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

Private Placement Subscriptions

 

On June 29, 2026, Mangoceuticals, Inc. (the “Company”, “we” and “us”) entered into a Subscription Agreement with an accredited investor (the “Investor”), pursuant to which the Investor purchased 850,000 shares of restricted common stock from the Company, for $0.32 per share, or a total of $272,000. The Subscription Agreement included customary representations and warranties of the Investor and the Company and includes piggyback registration rights for a period of one year following the dates of the subscription.

 

The description of the Subscription Agreement above is not complete and is qualified in its entirety by the full text of the form of Subscription Agreement, a copy of which is attached hereto as Exhibit 10.1, and which is incorporated by reference into this Item 1.01 in its entirety by reference.

 

Item 3.02. Unregistered Sales of Equity Securities.

 

The information set forth in Item 1.01 above is incorporated by reference into this Item 3.02 in its entirety.

 

The Company claims an exemption from registration for the issuance of the shares to the Investor (as discussed in Item 1.01, above), pursuant to Section 4(a)(2) and/or Rule 506 of Regulation D of the Securities Act of 1933, as amended (the “Securities Act”), since the offer and sale of such shares did not involve a public offering and the recipient was an “accredited investor” and had access to similar information as would be included in a registration statement under the Securities Act. The securities were offered without any general solicitation by us or our representatives. No underwriters or agents were involved in the foregoing offers and sales and we paid no underwriting discounts or commissions. The securities are subject to transfer restrictions, and the securities contain an appropriate legend stating that such securities have not been registered under the Securities Act and may not be offered or sold absent registration or pursuant to an exemption therefrom. The securities were not registered under the Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws.

 

Item 9.01 Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
10.1*   Form of Common Stock Subscription Agreement
104   Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).

 

* Filed herewith.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MANGOCEUTICALS, INC.
   
Date: July 2, 2026 By: /s/ Jacob D. Cohen
    Jacob D. Cohen
    Chief Executive Officer

 

 

 

FAQ

What did Mangoceuticals (MGRX) announce in this 8-K filing?

Mangoceuticals announced a private placement where an accredited investor purchased 850,000 restricted common shares at $0.32 each, providing $272,000 in proceeds. The transaction was completed through a Subscription Agreement with customary terms and no underwriting involvement.

How many shares did Mangoceuticals (MGRX) issue and at what price?

Mangoceuticals issued 850,000 shares of restricted common stock at $0.32 per share. This private placement resulted in total gross proceeds of $272,000, all from a single accredited investor under a Subscription Agreement.

What registration rights did the investor receive from Mangoceuticals (MGRX)?

The investor received piggyback registration rights for one year after the subscription date. These rights allow the investor’s shares to be included in certain future registration statements that Mangoceuticals may file, subject to the terms of the Subscription Agreement.

Under what securities law exemptions did Mangoceuticals (MGRX) issue the shares?

Mangoceuticals relied on exemptions from registration under Section 4(a)(2) and/or Rule 506 of Regulation D. The offering was made to an accredited investor without general solicitation and was not registered under the Securities Act or state securities laws.

Were any underwriters or commissions involved in Mangoceuticals’ (MGRX) private placement?

No underwriters or agents participated in the private placement, and Mangoceuticals paid no underwriting discounts or commissions. The shares were offered directly by the company to an accredited investor in a non-public transaction.

Are the new Mangoceuticals (MGRX) shares freely tradable?

The newly issued shares are restricted securities and carry transfer restrictions. They bear a legend stating they are not registered under the Securities Act and cannot be offered or sold in the United States without registration or a valid exemption.

Filing Exhibits & Attachments

4 documents